Investigators reviewed drug retention and response rates in patients with axial spondyloarthritis after their first initiation with tumor necrosis factor inhibitors.
Based on new evidence and an expert consensus, the American College of Rheumatology (ACR), the Spondylitis Association of America, and the Spondyloarthritis Research and Treatment Network released updated recommendations for the treatment of axial spondyloarthritis (SpA), which comprises ankylosing spondylitis (AS) and nonradiographic axial SpA. This report was published in Arthritis Care & Research. A systematic…
![The clustering of RA among family members suggests a strong genetic link, supported by the identification of specific alleles within defined loci in the human leukocyte antigen (HLA) system that are associated with increased risk for the development of anticitrullinated protein antibody-positive and anticitrullinated protein antibody-negative RA. [3]](https://1fxghyessyy2gaob23ygwzph-wpengine.netdna-ssl.com/wp-content/uploads/sites/18/2019/01/thinkstockphotos15641636741_1010901-544x306.jpg)
Researchers examined the effects of HLA-B27 and HLA-DRB1 alleles on the intestinal microbiome of healthy individuals.
Updated recommendations for the treatment of ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis were presented.
The FDA has approved Taltz (ixekizumab; Eli Lilly) for the treatment of adults with active ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis.
Researchers examined complement activation in spondyloarthropathies, before and after initiation of antirheumatic treatment, and the link between complement activation and markers of inflammation and cardiovascular risk.
The research determines the incidence rate of herpes zoster in patients with AS vs those without AS.
Patients with ankylosing spondylitis who achieve the ASAS40 end point have less spinal pain at night, less fatigue, better sleep, and improved quality of life.
Secukinumab therapy has been associated with low rates of immunogenicity among patients with psoriatic arthritis and ankylosing spondylitis.
Secukinumab-treated patients with AS were found to have a numerically higher proportion of radiographic non-progressors compared with biologic-naïve NSAID treated patients.
